For example, it has been recently demonstrated that tumors carrying KRAS/TP53 mutations have an enhanced tumor inflammation, increased PD-L1 expression and tumor-infiltrating lymphocytes (TILs) and, consequently, there is a remarkable clinical benefit wit ICIs (48). Here, TP53 is linked to neoplasm.